Skip to main content

Advertisement

SpringerLink
Log in

The prognostic of p27kip1 in ovarian cancer: a meta-analysis

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

P27kip1 is a negative cell cycle regulator that plays an important role in tumor suppression. Deregulation of p27kip1 is commonly observed in many human cancers. Numerous studies about p27kip1 are reported in clinical patients despite variable data for the prognostic of p27kip1 expression. Here we report a meta-analysis of the association of p27kip1 expression with the survival of ovarian cancer.

Methods

PubMed and Web of science were searched for studies evaluating expression of p27kip1 and prognostic in ovarian cancer. Published data were extracted and computed into odds ratios (ORs) for death at 3 and 5 years. Data were pooled using the random-effect model. All statistical tests were two-sided.

Results

Analysis included 9 studies: six studies were reported in European, three studies were reported in American, and one study was reported in Asian. Loss of p27kip1 was associated with worse overall survival (OS) at both 3 years [OR = 2.61, 95 % confidence interval (CI) 1.95–3.49, p < 0.05] and 5 years (OR = 3.01, 95 % CI 2.17–4.17, p < 0.05). Among studies with different ethnicity (European, American and Asian), the results showed a more significant association in European, including Italy, Germany, and Greece [for both 3-year OS (OR = 3.53, 95 % CI 2.37–5.26) and 5-year OS (OR = 3.66, 95 % CI 2.30–5.83)].

Conclusions

Loss of p27kip1 is associated with worse survival in ovarian cancer. The development of strategies target p27kip1 could be a reasonable therapeutic approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Brewer MA, Johnson K, Follen M et al (2003) Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9:20–30

    PubMed  CAS  Google Scholar 

  2. Bast RC Jr, Urban N, Shridhar V et al (2002) Early detection of ovarian cancer: promise and reality. Cancer Treat Res 107:61–97

    PubMed  Google Scholar 

  3. Sanseverino F, Torricelli M, Petraglia F et al (2003) Role of the retinoblastoma family in gynecological cancer. Cancer Biol Ther 2:636–641

    Article  PubMed  CAS  Google Scholar 

  4. Zhang D, Vuocolo S, Masciullo V et al (2001) Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Oncogene 20:7935–7944

    Article  PubMed  CAS  Google Scholar 

  5. Bali A, O’Brien PM, Edwards LS et al (2004) Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10:5168–5177

    Article  PubMed  CAS  Google Scholar 

  6. Masciullo V, Ferrandina G, Pucci B et al (2000) p27kip1expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 6:4816–4822

    PubMed  CAS  Google Scholar 

  7. Hashimoto T, Yanaihara N, Okamoto A et al (2011) Cyclin D1 predicts the prognosis of advanced serous ovarian cancer. Exp Ther Med 2:213–219

    PubMed  PubMed Central  Google Scholar 

  8. Hurteau JA, Allison BM, Brutkiewicz SA et al (2001) Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer. Gynecol Oncol 83:292–298

    Article  PubMed  CAS  Google Scholar 

  9. Masciullo V, Sgambato A, Pacilio C et al (1999) Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 59:3790–3794

    PubMed  CAS  Google Scholar 

  10. Farley J, Smith LM, Darcy KM et al (2011) Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group study. Gynecol Oncol 121:395–401

    Article  PubMed  CAS  Google Scholar 

  11. Schmider-Ross A, Pirsig O, Gottschalk E et al (2006) Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. J Cancer Res Clin Oncol 132:163–170

    Article  PubMed  CAS  Google Scholar 

  12. Psyrri A, Bamias A, Yu Z et al (2005) Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res 11:8384–8390

    Article  PubMed  CAS  Google Scholar 

  13. Rosen DG, Yang G, Cai KQ et al (2005) Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11:632–637

    PubMed  CAS  Google Scholar 

  14. Korkolopoulou P, Vassilopoulos I, Konstantinidou AE et al (2002) The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 85:404–414

    Article  PubMed  Google Scholar 

  15. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834

    Article  PubMed  CAS  Google Scholar 

  16. Tsihlias J, Kapusta LR, DeBoer G et al (1998) Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542–548

    PubMed  CAS  Google Scholar 

  17. Slingerland JM, Hengst L, Pan CH et al (1994) A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 14:3683–3694

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Polyak K, Lee MH, Erdjument-Bromage H et al (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66

    Article  PubMed  CAS  Google Scholar 

  19. Nakayama K, Ishida N, Shirane M et al (1996) Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707–720

    Article  PubMed  CAS  Google Scholar 

  20. Fero ML, Rivkin M, Tasch M et al (1996) A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85:733–744

    Article  PubMed  CAS  Google Scholar 

  21. Muraoka RS, Lenferink AE, Simpson J et al (2001) Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J Cell Biol 153:917–932

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. McAllister SS, Becker-Hapak M, Pintucci G et al (2003) Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 23:216–228

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Duncan TJ, Al-Attar A, Rolland P et al (2010) Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol 29:8–18

    Article  PubMed  Google Scholar 

  24. Sims AH, Zweemer AJ, Nagumo Y et al (2012) Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer 106:1779–1789

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83:1021–1032

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Le XF, Mao W, He G et al (2011) The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst 103:1403–1422

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Li CF, Wang JM, Kang HY et al (2012) Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin Cancer Res 18:1598–1610

    Article  PubMed  CAS  Google Scholar 

  28. Hershko DD (2010) Cyclin-dependent kinase inhibitor p27 as a prognostic biomarker and potential cancer therapeutic target. Future Oncol 6:1837–1847

    Article  PubMed  CAS  Google Scholar 

  29. Zhao H, Bauzon F, Fu H et al (2013) Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell 24:645–659

    Article  PubMed  CAS  Google Scholar 

  30. Shi YC, Zhao H, Yin C et al (2013) C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades. Dig Liver Dis 45:844–851

    Article  PubMed  CAS  Google Scholar 

  31. Wu X, Liu T, Fang O et al (2013) miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27(kip1). Oncogene. doi:10.1038/onc.2013.108

    Google Scholar 

  32. Mills AM, Ly A, Balzer BL et al (2013) Cell cycle regulatory markers in uterine atypical leiomyoma and leiomyosarcoma: immunohistochemical study of 68 cases with clinical follow-up. Am J Surg Pathol 37:634–642

    Article  PubMed  Google Scholar 

  33. Fei M, Zhao Y, Wang Y et al (2009) Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. Cancer Invest 27:52–59

    Article  PubMed  CAS  Google Scholar 

  34. Levanon K, Sapoznik S, Bahar-Shany K et al (2013) FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene. doi:10.1038/onc.2013.394

    PubMed  PubMed Central  Google Scholar 

  35. Siu MK, Wong ES, Kong DS et al (2013) Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 32:3500–3509

    Article  PubMed  CAS  Google Scholar 

  36. Fu G, Peng C (2011) Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells. Oncogene 30:3953–3966

    Article  PubMed  CAS  Google Scholar 

  37. Chock KL, Allison JM, Shimizu Y et al (2010) BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Cancer Res 70:8782–8791

    Article  PubMed  CAS  Google Scholar 

  38. Kim TH, Lee HH, Chung SH, et al. (2015) Expression of p27 and Jun activation domain-binding protein 1 in endometriosis. Arch Gynecol Obstet. 2015 Feb 10. [Epub ahead of print]

  39. Iwasaki S, Sudo T, Miwa M et al (2013) Endometrial stromal sarcoma: clinicopathological and immunophenotypic study of 16 cases. Arch Gynecol Obstet 288(2):385–391

    Article  PubMed  CAS  Google Scholar 

  40. Hasegawa K, Torii Y, Ishii R, Oe S, Kato R, Udagawa Y (2011) Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch Gynecol Obstet 284(6):1515–1521

    Article  PubMed  CAS  Google Scholar 

  41. Konecny GE, Wang C, Hamidi H et al (2014) Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. doi:10.1093/jnci/dju249

    PubMed  PubMed Central  Google Scholar 

  42. Tothill RW, Tinker AV, George J et al (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198–5208

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Scientific Foundation of China Grant (No. 30872999;81372480), a grant RC2011033 from Revitalize and defend the key talent’s subsidy project in science and education of department of public health of Jiangsu Province; a grant 201318101-13 from Xinjiang Uygur Autonomous Region Natural Science Foundation of China, Wuxi hospital management center medical technology development fund (YGM1401), Wuxi science and technological developmental project (CSE31N1427). The authors have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Genetic Laboratory, Wuxi Hospital for Maternal and Child Health Care, The Affiliated Hospital of Nanjing Medical University Wuxi, 48 Huaishu-xiang, Wuxi, Jiangsu, 214002, China

    Mudan Lu, You Wang, Fei Xu, Jingying Xiang & Daozhen Chen

Authors
  1. Mudan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. You Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingying Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daozhen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Mudan Lu or Daozhen Chen.

Ethics declarations

Conflict of interest

The authors stated that there are no conflicts of interest regarding the publication of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, M., Wang, Y., Xu, F. et al. The prognostic of p27kip1 in ovarian cancer: a meta-analysis. Arch Gynecol Obstet 293, 169–176 (2016). https://doi.org/10.1007/s00404-015-3817-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-015-3817-8

Keywords

Search

Navigation